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ABSTRACT 
There is an epidemic of chronic kidney disease of unknown cause (CKDu) clustering in rural communities of low-
and-middle income countries. The International Society of Nephrology’s International Consortium of 
Collaborators on CKD of Unknown Etiology established a workgroup to develop uniform approaches to detecting 
CKDu at a population-level. The group have outlined methodologies to detect CKDu using routine data or 
population-based studies along with elements of minimal data sets that could be used to provide robust and 
comparable measures of CKDu burden. Use of these common approaches will allow the international nephrology 
community to speak with a single voice when advocating for resources to support research, prevention and 
treatment of CKD in low-income settings and CKDu specifically. 
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1. INTRODUCTION 
There is an epidemic of chronic kidney disease (CKD) clustering in rural communities, predominantly in a number 
of low-and-middle income countries1. Tens of thousands of working-aged adults are estimated to have died from 
the disease in Central America2 with similar numbers in Sri Lanka3. Similar diseases have been reported 
elsewhere, e.g. rural regions or communities in India4, North5 and West6 Africa. Those affected do not have 
common risk factors or underlying conditions that lead to CKD, e.g. diabetes, immune-mediated 
glomerulonephritis or structural renal disease. In instances where histopathology is available, the predominant 
feature is tubular atrophy and interstitial fibrosis7-10. Although it is currently unclear whether there is a unified 
underlying cause, these conditions have been collectively termed CKD of unknown cause (“CKDu”). Other terms 
used include CKD of non-traditional Cause11, Mesoamerican Nephropathy12, Chronic Intestinal Nephritis in 
Agricultural Communities13 and Kidney Disease of Unknown Cause in Agricultural Laborers14 but we have chosen 
CKDu as the most agnostic terminology.  
 
The current clinical and research landscape in CKDu consists of multiple similar, but non-concordant approaches 
to individual-level diagnosis11,15 and detection at the population-level15-17. In combination with the ongoing lack of 
treatment or prevention strategies the heterogeneity in identification of CKDu is a significant obstacle to 
combating the disease.  
 
A uniform approach to detecting CKDu on a population-level would allow comparisons between studies and 
regions, providing valuable data for healthcare agencies and a basis for understanding key risk factors for disease. 
However even when “gold-standard” diagnostic investigations are available, no single approach will capture CKDu 
with complete certainty, and, depending on the reasons for evaluation, clinicians or researchers may accept 
differing levels of uncertainty. Nonetheless a uniform approach enables comparability and allows the 
international nephrology community to speak with a single voice in attempts to advocate for research, prevention 
and treatment resources.  
 
To this end the International Society of Nephrology’s International Consortium of Collaborators on Chronic Kidney 
Disease of Unknown Etiology (i3C) created a workgroup to guide a common approach to the detection of CKDu. 
This work shares many goals, and aims to be complementary to, the recent Resolution on Chronic Kidney 
Disease18 from the Pan American Health Organization.  We list different study populations that might be of 
interest alongside kidney-specific and other measures that could be used to determine the burden of disease.  
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Finally, we recommend a number of elements for a ‘minimum dataset’ endorsed by the i3C, for use in studies 
aimed at quantifying and comparing disease burden.  
 
Key to this work is the recognition that there is currently no consensus on the case definition(s) for CKDu, and 
existing definitions may be refined in future11,19. Therefore the aim should be to obtain key information that can 
be used in a variety of definitions of CKDu now and going forward. Hence this approach is designed to estimate 
the extent of ESRD or impaired kidney function in a specific region of interest, and then determine the proportion 
of that estimate attributable to the “CKDu” as later defined.  
 
We selectively focus on detection, rather than surveillance, as an initial step to building consensus approaches. 
Although the methodologies described could be part of wider surveillance efforts, systems required for continual 
monitoring, real-time data interpretation and reporting are not discussed.  Furthermore we also recognize 
diagnosis of CKDu in individuals can be challenging, particularly in resource-constrained settings; potential 
strategies are discussed further in the Supplementary Material.   
 
We have divided detection efforts into: 
(i) Passive detection based on routine data collected for clinical or administrative purposes, and,  
(ii) Active detection undertaken specifically for the purposes of determining disease prevalence (based on 
prospective epidemiological studies or extant datasets for the study of non-communicable diseases in general).  
 
Recommended approaches and the minimum dataset are highlighted in the tables.  
2. PASSIVE DETECTION. 
Death certification, and end-stage renal disease (ESRD) registries are potential data sources (Table 1) that can 
help identify regions as “hot spots” of kidney disease. Indeed, such approaches have been a key first step in 
recognising existing CKDu epidemics 20,21. Two issues arise when using routine data:  
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1. Scarce and poor-quality routine data collection in many of the potentially affected regions. The World Health 
Organization (WHO) and Institute for Health Metrics and Evaluation have published  global estimates on cause-
specific deaths included those attributed to kidney disease22. The methodology underlying WHO estimates of 
cause-specific mortality is available elsewhere22 however data-quality, including that based on verbal autopsy-
based diagnosis of CKD23,  from almost all regions likely to be impacted by CKDu is suboptimal (Figure 1).  
 
2. Difficulty differentiating whether recorded kidney disease is due to the CKDu. Misattribution of cause, a major 
challenge worldwide but particularly in settings where biopsies are not routinely obtained, could lead to 
misclassification as CKDu where a biopsy would have provided a diagnosis (e.g. IgA Nephropathy). 
 
Additionally, CKDu is unlikely to be recorded specifically in death registries so underlying knowledge of diabetes, 
(and ideally rates of CKD attributed to diabetes) are key to generate useful estimates (as diabetes is the 
commonest cause of ESRD). Dialysis and transplant registries usually record cause-specific diagnoses albeit 
subject to misclassification as well; however terminology may vary and in most low-resource settings, the 
registries capture only a small fraction of patients reaching ESRD. 
3. ACTIVE DETECTION  
Active detection of CKDu will involve the systematic survey of populations to detect disease. This may involve new 
studies focused on CKDu or the use of existing datasets or plans for non-communicable disease surveillance, 
where minimum requirements are met. Indeed, there may be significant gains to be made in terms of rapid 
acquisition of prevalence data by accessing or modifying existing studies/processes (e.g. WHO STEPS24 
instruments or USAID Demographic and Health Surveys25).  
Populations and study design 
The possible populations and study approaches to active detection are outlined in Table 2. A critical feature of the 
reporting of all efforts is a description of the geographical area along with both the source population and the 
study responders so that conclusions about the representativeness of the study sample be drawn. These 
summary response rate data should be stratified by sex and age with adequate granularity to detect response 
bias (e.g. 10-year age bands). 
Numerator (determined by measures of kidney dysfunction) 
As alluded to in the introduction our aim is not to presuppose a definition of CKDu, but to provide a framework 
for the collection of data that will allow detection of CKD in a reproducible manner, to which a number of 
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definitions of CKDu to be applied (e.g. using different thresholds of kidney function or presence or absence of 
proteinuria or comorbidity). Importantly The Kidney Disease Improving Global Outcomes collaboration provides 
internationally accepted criteria for the clinical identification of CKD26. Given the asymptomatic nature and other 
attributes of CKDu population-based detection methods for this disease need to be based on measures of kidney 
function (estimated glomerular filtration rate, eGFR). Although the KDIGO definition of CKD requires two-
measurements of eGFR26 the multiplicative increase in resources required to re-contact participants after a 
prolonged period means that, in common with a large body of CKD-epidemiology, the i3C workgroup 
recommends accepting initial detection efforts based on a single eGFR estimate only. Furthermore, definitions of 
CKD use a threshold of GFR, however to allow maximum flexibility i3C advocates collection and reporting of the 
entire distribution of GFR values along with numbers below a particular (CKD) threshold. The different methods to 
quantify renal dysfunction are outlined in Table 3. 
Other important data items 
Key associations of CKDu at a population level are the absence of heavy proteinuria, and other causes of, or risk 
factors for, CKD and the socio-demographic characteristics of those that are affected. Therefore, information on 
these variables are needed to produce informative prevalence estimates (Table 3). The recommendations have 
been kept to a minimum to ensure minimal resource implications and allow the use of extant datasets.  
  
4. APPLICATION OF SUGGESTED APPROACH 
There is an urgent need for data that are comparable regionally and internationally, and the aim of a minimum 
data set(s) is/are to obtain the key information that can be used to define CKDu currently and in future (see 
supplementary material for an example). Such a dataset is contingent upon an international agreement to collect 
uniform data but it is presumed and expected that researchers, agencies and service providers should collect 
additional data to meet their own specific needs..    
 
Active or passive approaches may be more or less appropriate for these different aims including: 
1. Alerting health services/communities/researchers to a possible problem of CKDu,  
2. Estimating scope and scale of CKDu within populations  
3. Determining secular trends in CKDu 
4. Insight into disease aetiology 
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Therefore, it may be appropriate to apply two (or more) approaches in any single region. A protocol using a 
similar minimum dataset to undertake population-level detection has recently been published and is already 
being used in a number of settings in South Asia, Latin America and Sub-Saharan Africa27. 
5. SUMMARY 
A uniform approach to detecting CKDu on a population-level allows the understanding key risk factors for disease, 
provides valuable data for healthcare agencies and establishes a basis for comparisons between regions and 
research studies. This document elaborates the methodology to detect CKDu via passive or active detection and 
suggests criteria for minimum data set. Such a common approach would allow the international nephrology 
community to speak with a single voice in attempts to advocate for research, prevention and treatment resources 
for CKD in general, and for CKDu in specific areas. 
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6. FIGURE LEGENDS AND TABLES 
 
Figure 1. Map showing data-quality of cause-of-death by WHO member state as assessed by the 2016 Global 
Health Estimates project. Data from http://www.who.int/healthinfo/global_burden_disease/en/. WHO advises 
data from countries labeled in green (high completeness and quality) can be used for time or country 
comparisons whereas data from countries labeled yellow (moderate quality issues) or orange (severe quality 
issues) should only be used with caution. Estimates of cause-of death from countries labeled red (unavailable or 
unusable) should not be used for comparisons or policy purposes. Note: The impact of the availability of 
treatment for ESRD in a region may impact on estimates of the burden of chronic kidney disease (of any cause) 
from death registries as patients receiving renal replacement therapy may have a non-kidney related primary 
cause of death recorded and ESRD only recorded as a contributory cause (or not at all) . 
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attributable to diabetic 
kidney disease, or if not 
available, adjust for age-
standardized diabetes 
prevalence^   
 









identify hot spots  
Sometimes difficult to 
disaggregate to regional 
or state level  
  
Data are non-specific and 
not be able to 
differentiate CKDu from 
high rates of cause-
specific kidney disease 
(e.g., IgA nephropathy). 
Cause of ESRD or 
cause of kidney 
disease leading to 
death 
 
Data on the 
proportion of (non-
CKD) deaths of 
unknown cause 
should also be 








of patients with 








Only include those with 
‘unknown’ cause if 








identify hot spots 
 
May also able to 
give a regional or 
state-level estimate 
if data are 
available. 
Not available, or not 
representative of entire 
burden of (untreated) 




Attribution of kidney 
disease cause may be 
incorrect 
(or both known causes 
and CKDu may coexist)  
Occupation of 
persons with ESRD   
 
Family history of 
persons with ESRD  
 
We propose, that to the extent feasible, the data should be disaggregated to regional (in addition to national) levels and presented by age- and sex-strata so localized clustering 
can be identified.   
# The latest WHO and IHME Global burden of disease estimates include age-specific kidney disease attributable death estimates   
*To referent World population as recommended by WHO http://www.who.int/healthinfo/paper31.pdf?ua=1 
^These data are available on a national level at least via the IDF for many countries; the WHO also provides estimates for age-specific deaths due to diabetic kidney disease 
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Table 2 Study populations (denominator) and sampling approach 




Random (or stratified 




Representative of population prevalence 
Fieldwork can be challenging and response 
variable 






All comers Not representative and prone to major issues 
in interpretation due to selection bias 
No  
Workplace population Random sample, whole 
population  
Can be easier to capture participants than 
community based studies 
Investigators need to be sensitive to differing 
incentives between employees and employers 
to take part in studies 
Unlikely to be representative of community as 
a whole and may be misleading with regard to 
population prevalence and risk factors 
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Table 3 Kidney function measures (to determine the numerator) 
GFR Measures Advantages/disadvantages Recommended by i3C for 
minimum data set 
eGFR from creatinine - 
SINGLE MEASURE 
(CKD-EPI formula)* 
Serum creatinine measures available in most countries 
IDMS referenced methods critical to allow comparison 
between centres 
Population specific non-renal sources of creatinine affect 
estimates (meat consumption, muscle mass/breakdown)** 
Yes, if IDMS referenced measures 
 
 
eGFR from creatinine - 
REPEAT MEASURE 
As above 
Reduces misclassification of AKI as CKD, aligns with KDIGO 
clinical guideline 
Requires recontact of all those with abnormal results after > 3 
months. 
Yes  if resources allow but not as 
part of a minimum dataset 
 
eGFR from cystatin C Cystatin C based eGFR may be less dependent on non-renal 
factors 
Impact of ethnicity on equations used to calculate the eGFR 
using cystatin C are unknown 
No accepted method for standardization across laboratories 
yet 
Expensive  
Not yet but may become the 
international standard 
 
Bio banking samples may be 
advised 
measured GFR Likely overcomes the ethnicity dependent bias in eGFR 




We acknowledge that comparing GFR between populations internationally is problematic as the normal distribution of this 
variable is unknown in many of the groups/regions28 and the implications for health of a particular GFR is also unknown. These 
issues are felt to be beyond the remit of the i3C and require substantial global efforts to address but are nonetheless accepted. 
Beyond this issue, the GFR is generally estimated from serum markers (the eGFR) and the GFR estimating equations have not 
been validated in many of the relevant populations29, a particular issue when comparing eGFR distributions internationally as this 
will lead to ethnicity-specific differential bias. Validated eGFR equations in all relevant populations are unlikely to be available in 
the short term so this is again accepted as a limitation of the proposed collaborative approach. Furthermore although the i3C 
suggest estimates of the prevalence of impaired eGFR for the purposes of regional or international comparisons can be based on 
a single eGFR measurement only this does not detract from the responsibility to refer those with an abnormal finding (e.g. 
elevated creatinine, hypertension, protein/glycosuria) at initial survey to local health services and, it is recognized that 
investigators with resources may want to perform repeat measures in participants with abnormal results after an interval >3 
months to reduce misclassification of episodes of acute kidney injury as CKD.  
*CKD-EPI equation although not validated in many populations of interest has been shown to be more precise in the normal and 
near-normal GFR range that will be predominant in prevalence studies.  
** Measures such as self-report of meat intake/vegetarianism30 and estimates of body composition e.g. DEXA or bioelectrical 
impedance31 measurements may be useful in adjusting for the impact of non-renal sources of creatinine when comparing eGFR 
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Table 4 Other important data items. 
Non-GFR 
measures 
Rationale / Advantages / Disadvantages Method Recommended by i3C for 
minimum data set 
Age  Rates of CKD and CKDu are age- dependent Self-report Yes 
Sex Rates of CKD and CKDu are sex- dependent Self-report Yes 
Ethnicity / racial 
group 
Rates of CKD and CKDu are ethnicity 
dependent 
 
Can be difficult to capture and may be 
sensitive in some popualtions 
Self-report Yes 
Occupation  CKDu has been mainly described in agricultural 
communities/workers. 
 
Occupational history can be very difficult to 




Yes, although it is acknowledged 
that international comparisons of 




Many studies demonstrate an association 
between social deprivation and CKDu 




Yes, can be reported as 
primary/secondary education 
and/or quartiles/quintiles of income 
Address or 
geolocation  
CKDu has generally been described in rural 
populations and at low-altitudes 
 
Self-report or cluster level 
data 




CKDu has been described in tropical regions Regional routine data (e.g. 
average daytime and 
nighttime temperatures) 
Yes  
Diabetes Although diabetes might co-exist with CKDu 
the high prevalence of diabetic nephropathy 
means most estimates of CKDu have excluded 
those with diabetes* 
Self-report of diagnosis or 
medication 
 
Yes, discriminate type 1 (insulin 
dependent at diagnosis) from type 2 
if possible 
  Glycosuria No, except if performing urinalysis 
  Fasting glucose or HbA1c, If resources allow 
Hypertension Severe hypertension appears atypical in CKDu 
and may indicate alternative causes of CKD.  
 




  Direct measurement  
 





Drugs may cause CKD (or CKDu) 
 
Self-report If resources allow, recognising that 
international comparisons are likely 
to be difficult 
Infections Likely to differ by population 
Many of those affected will be undiagnosed 
Self-report No 
Snake bite Important cause of kidney injury  Self-report If resources allow where relevant 
History or cause of 
CKD 
 
Many of those with CKD are unaware, or even 
if aware may not know the cause 
Self-report No 
Family history of 
CKD 
Family history of CKD has been described in 
CKDu 











If resources allow, recognising that 
simple assessments are likely to be 




Difficult to capture Self-report If resources allow, recognising that 
simple assessments are likely to be 




No or low-level proteinuria typical for CKDu  
urinalysis cheap but affected by urinary 
concentration 
Urinalysis Yes, or ACR 
Quantified 
albuminuria 
more expensive but quantitative  Albumin/creatinine ratio Yes, or urinalysis 
Quantified 
proteinuria 
Less specific than ACR Protein/creatinine ratio No 
Haematuria  May help exclude other forms of CKD e.g. 
Schistosomiasis 
Urinalysis Yes, if performing urinalysis for 
protein 
Imaging Smooth small kidneys; operator dependent 
expensive and difficult at scale 
Ultrasound No 
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* Note that CKDu can be seen in patients with diabetes, so although an individual with diabetes might be excluded from the denominator used in 
detection efforts a clinical diagnosis of CKDu may still be appropriate.  
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Figure 1  
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Current clinical case definitions  
 
Although the i3C does not aim to agree on clinical or epidemiological case definitions, the World Health 
Organization, Centers for Disease Control (CDC), and other expert epidemiology organizations have created a 
template for a typical case definition for “an outbreak” investigations.  It is arguable whether CKDu classifies as an 
outbreak but it is instructive to review these concepts and consider how they may apply to CKDu.  The CDC for 
example advises that a case definition with two components: clinical and laboratory.  The clinical criteria typically lay 
out person, place, and time.  In addition to varying by levels of certainty (Annex Table 2), case definitions can (and 
likely should) vary over time as more information—typically diagnostic testing—becomes available.   
 
Annex Table 2 CDC outbreak investigation categorisation 
  Advantage Disadvantage Applicable to CKDu? 
Suspect Typically based on one 
or two clinical criteria 
alone   
Could be very sensitive—
i.e., capture any and all at 
risk populations  
Useful in highly 
transmissible diseases, for 
purposes of isolation and 
prevention of further 
spread  
Not specific, could 
be misleading by 
inflating numbers 
of afflicted persons  
Probably, in specific 
areas if certain 
‘criteria’ can be 
agreed upon 
Probable  Based on several 
clinical criteria +/- one 
or two laboratory 
criteria   
Offers an acceptable 





Yes, if can be 
operationalized to 
‘field conditions’ in 
low-resource 
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Confirmed  Based on meeting all 
of the clinical criteria, 




Offers the highest 
specificity 
Not feasible or 
practical in many 
instances  
Yes, for clinical 
management, 
especially if a 
specific diagnostic 
tool that does not 
require biopsy can 





feasible in many 
areas  
 
Recently, experts from Mesoamerica created a clinical and epidemiological definition for CKDu using a Delphi 
process, and further cited in the Pan American Health Organization’s Resolution on Chronic Kidney Disease in 
Agricultural Disease.  At a World Health Organization coordinated conference held in Sri Lanka in October 2016, 
experts proposed a ‘suspected’ and ‘confirmed’ classification system which builds on different sources of 
information to classify the condition (Annex table 3).  These definitions are not identical, and the positive predictive 
value of these definitions against a biopsy is unknown but they indicate examples of systematic diagnoses and 
surveillance tools for CKDu.  
 
Unique considerations that may be important in creating a clinical case definition of CKDu include:  
• Defining place or time period: It is possible CKDu is unique to certain regions (Mesoamerican, Sri Lankan, 
Indian and other regions) and that “place or residence” needs to be part of the case definition. The 
limitations of this are that geography may change.  
• Limitations of diagnostic testing: no “gold standard” except kidney biopsy, the availability of which is 
limited in Mesoamerican countries in particular  
• The existence of CKD without a known cause is widespread in clinical practice globally: but must be 
differentiated from the epidemic levels of disease seen in rural communities as the former reflects late 
diagnoses and rarer diseases and in almost all cases will be a different clinical entity to CKDu 
• Low –income regions affected: meaning agreed efforts aimed at labeling a patient as having CKDu need to 
be possible with limited resources 
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Comparison of case definitions for confirmed, suspect and probable cases of CKDu by Mesoamerican and Sri Lankan 
expert societies  
 
 Meso America Sri Lanka  
Confirmed 
Presence of • eGFR < 60 
and/or albuminuria (30-to <3000 mg/g) 
and/or  
• Urinary sediment abnormalities including 
hematuria  
And/or 
• Renal tubular disorder 
And 
• Age 2 to 59 
And 
• No ultrastructural abnormalities on kidney 
Ultrasound  
• eGFR < 60 and/or albuminuria > 
30 mg/g and 
• histopathological features 




Exclusion of • Diabetes with microvascular disease 
• Hypertension with target organ damage 
or BP >= 160/100 
• Autoimmune, hematologic, urologic or 
hereditary kidney disease 
• Repeated exposure to contrast 
Criteria listed under suspect and 
probable CKDu 
Suspect 
Presence of • CKD as measured by eGFR < 60 ml/min or 
albuminuria > 30 mg/g 
• Age < 60 years  
 
• eGFR < 60 or albuminuria > 30 
mg/g 
Exclusion of • Type 1 diabetes 
• Self reported hypertension 
• Self reported  
Autoimmune, hematologic or hereditary 
kidney disease 
 
• Diabetes (self reported or 
diagnosed in clinic) 
• Hypertension on treatment or BP 
>=160/100 on two measurements 
• Proteinuria > 2 g/day  
I3Cdetection v2.1 21/12/2017 
21 
Probable 
Presence of  • A suspect case with CKD on repeat testing  • A suspect case with CKD on 
repeat testing performed 12 
weeks later 
 
Exclusion of -- • Ultrastructural abnormalities on 
ultrasound   
• Clinical suspicion of other known 
causes of CKD  
• Diabetes based on fasting plasma 
glucose < 126 mg/dL. 
• Hematuria 





Clinical diagnosis of CKDu  
The i3C recognizes the challenges for nephrologists working in endemic regions and tasked with evaluating patients 
detected as having abnormal kidney function via population-based screening programs, or those presenting with 
symptoms of kidney disease.  Given the controversy in consensus on a case definition, how does a nephrologist 
decide whether such a patient has CKDu (with the corresponding tubulo-interstitial disease), especially if kidney 
biopsy is not available?  Another important diagnostic tool, urine albumin to creatinine ratios, is expensive and 
variably available in endemic regions.      
With these considerations in mind, we outline the following principles if a non-biopsy based diagnosis is sought: 
1. Confirmation of persistently abnormal serum creatinine (with repeat serum creatinine and eGFR 
assessment) is critical*. Proteinuria alone without abnormal serum creatinine is unlikely to be correlated 
with tubulo-interstitial kidney disease on biopsy.  Since the diagnosis relies heavily on serum creatinine 
measurement, efforts to use laboratory equipment calibrated to IDMS standards are also essential.    
2. Urinary assessment is required even if performed with a dipstick alone. Substantial proteinuria or 
hematuria should prompt work up for other forms of kidney disease. More and more data indicate that 
CKDu, especially in its earlier stages, is not associated with significant proteinuria or hematuria.    
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3. Diabetes and hypertension can co-exist with CKDu.  In patients with these comorbidities, living in endemic 
areas but without significant proteinuria or hematuria, or evidence of end-organ damage from these 
diseases, CKDu should be considered.   
4. Where possible, kidney biopsy confirmed diagnosis is ideal.   
Based on these principles, one possible algorithm for a diagnosis of CKDu in endemic is presented below.   
 
*Within the framework of a clinical diagnosis, it is important to recognize that an acute tubulo-interstitial disease 
with some degree of recovery has recently been described in endemic regions. Patients are typically symptomatic 
with back pain or fever, and leukocytosis.  Biopsy could be considered in such cases, especially if evidence of acute 
and persistent rise in serum creatinine is noted, albeit only for a short period.    




Person living in endemic area 
with persistent, reduced eGFR
(<60 ml/min/1.73m2)
No accompanying diabetes 
after fasting glucose testing
Urine dipstick ≥ 1+
Confirmed with UACR or 
UPCR
Unlikely CKDu: likelihood of 
CKDu decreases if nephrotic 
range proteinuria  or if  
hematuria 
Urine dipstick negative 





Renal ultrasound without 
structural disease & no 
evidence of retinopathy 
Suspect CKDu, consider 
kidney biopsy 
Urine dipstick ≥ 1 
Confirmed with UACR or 
UPCR
Unlikely CKDu: likelihood of 
CKDu decreases  if 
+retinopathy 
Accompanying hypertension
Urine  dipstick negative
Renal ultrasound without 
structural disease
Suspect CKDu, consider 
kidney biopsy
Urine dipstick ≥ 1 
Confirmed with UACR or 
UPCR
Unlikely CKDu: likelihood of 
CKDu decreases if nephrotic 
range proteinura or if 
hematuria
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Example reporting of eGFR data from an active detection study using different definitions 
 
Once primary data are acquired a number of analyses can be performed using both the distribution of eGFR in a 
population or numbers of participants below a certain threshold.  For example, the prevalence of CKDu (as opposed 
to CKD of other causes) could be better approximated by excluding participants with diabetes or similarly restricting 
to those without heavy proteinuria. These criteria could be refined as additional information about the 
epidemiology of CKDu becomes available. Summary data from a simulated sample obtained from a hypothetical 
population with a high prevalence of CKDu amongst working age men is shown in the table below.  
 
 
Population Definition 1: All  Definition 2: Excluding self-
reported hypertension or 
diabetes1 
Definition 3: As definition 2 
but also excluding 
ACR>300mg/g 
 n eGFR (SD) n (%) with 
GFR<60 
eGFR (SD) n (%) with 
GFR<60 
eGFR (SD) n (%) with 
GFR<60 
Men        
18-30 97 112 (16) 12 (12) 115 (17) 11 (11) 115 (17) 11 (11) 
31-40 102 109 (15) 20 (20) 110 (18) 18 (18) 108 (18) 17 (17) 
41-50 89 99 (15) 13 (15) 101 (15) 10 (11) 104 (15) 9 (10) 
51-60 78 99 (13) 12 (15) 100 (13) 8 (10) 99 (13) 6 (8) 
>60 97 88 (17) 19 (20) 95 (18) 10 (10) 88 (17) 6 (6) 
Women        
18-30 111 121 (14) 4 (3) 125(10) 2 (2) 125(9) 2 (2) 
31-40 101 119 (15) 4 (4) 123 (11) 2 (2) 120 (10) 1 (1) 
41-50 96 117 (14) 4 (4) 120 (11) 1 (1) 118 (10) 1 (1) 
51-60 89 101 (15) 5 (6) 110 (13) 2 (2) 110 (13) 1 (1) 
>60 101 89 (16) 7 (7) 95 (14) 3 (3) 95 (14) 3 (3) 
 
1 It is important to underline the i3C group is not suggesting those with diabetes or high blood pressure 
cannot also get CKDu. However, the aim of this pragmatic type of analysis is to determine whether there 
is an excess of low eGFR across a population that is not attributable to another cause rather than to 
provide a clinical diagnosis at an individual level (for which approaches are outlined in Annex 2). 
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Data, collected with the same methodology, presented in this format can then be compared across time points and 
between regions.  Further stratification by urban/rural residence or other proposed CKDu risk factors might be 
informative. Additional adjustment for meat-intake and body composition indices is likely to reduce bias due to non-
renal sources of creatinine in these estimates.   
I3Cdetection v2.1 21/12/2017 
26 
 
